Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Bone marrow-derived cells for cardiovascular cell therapy: an optimized GMP method based on low-density gradient improves cell purity and function

Figure 2

Product stability. Nine sternal bone marrow samples were processed according to the new manufacturing method. The resulting product batches entered a stability program: they were stored at 10°C, and tested at 0-6-20-24 hours, for the following parameters: (A) Cell concentration. (B) Cell viability. (C) Percentage of mononuclear cells (MNC) (lymphocytes +μmonocytes). (D) Percentage of CD34+ cells. (E) Colony Forming Cell assay (CFC), to detect hematopoietic precursor cells. (F) Colony Forming Unit-Fibroblast assay (CFU-F), to detect mesenchymal precursor cells. (G) Invasion assay, to detect cells with invasion capacity. (H) Colony Forming Unit-Endothelial Cell assay (CFU-EC), to detect cells with angiogenic potential Data are expressed as relative values in respect to time 0. Each dot represents a single batch (identified by a distinct color), while black dashes indicate mean values. Relativevalue % = value at the indicated time point − value at time 0 value at time 0 x100.

Back to article page